Safety of JAK Inhibitors Approved for AD Treatment
Expert dermatologists review the safety data of the current JAK inhibitors approved for AD, highlighting adverse events and long-term safety data.
Source: hcplive.com
Page 5 - Peter Lio News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Peter Lio. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Peter Lio Today - Breaking & Trending Today
Indications and Efficacy of JAK Inhibitors for AD
Lisa Swanson, MD, PhD, reviews the indications for ruxolitinib, abrocitinib, and upadacitinib, as well as the clinical trial data on efficacy of these JAK inhibitors when treating AD.
Source: hcplive.com
Differentiating JAK Inhibitors From Other Therapies in AD
Expert dermatologists discuss the factors that differentiate JAK inhibitors from other AD therapies, highlighting itch scores as they relate to quality of life.
Source: hcplive.com
Targeting the JAK-STAT Pathway in AD
Alexandra Golant, MD; Christopher Bunick, MD, PhD; and Peter Lio, MD, comment on how targeting the JAK-STAT (signal transducer and activator of transcription) pathway with JAK inhibitors plays a role in managing AD.
Source: hcplive.com
Intro to Janus Kinase (JAK) Inhibitors for Treatment of Atopic Dermatitis (AD)
Peter Lio, MD, and Lisa Swanson, MD, PhD, provide an overview of Janus Kinase (JAK) inhibitors, their pathophysiology, and their mechanism of action in the treatment of atopic dermatitis (AD).
Source: hcplive.com